Barrow, Hanley, Mewhinney & Strauss
ANIK icon

Barrow, Hanley, Mewhinney & Strauss’s Anika Therapeutics ANIK Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-69,997
Closed -$2.12M – 340
2019
Q1 		$2.12M Sell
69,997
-2,180
-3% -$74.7K ﹤0.01% 231
2018
Q4 		$2.43M Buy
+72,177
New +$2.61M ﹤0.01% 218

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's ANIK Position: Q2 2019 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 69,997 shares — an estimated $2.12M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in ANIK in Q4 2018 and held it in 2 quarters. The position peaked at $2.43M in Q4 2018. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 69,997 Anika Therapeutics shares in Q2 2019, an estimated $2.12M.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Anika Therapeutics in Q4 2018 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Anika Therapeutics position peaked at $2.43M in Q4 2018.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2019, filed 13 Aug 2019.